TABLE 1.
Clinical dataa
| Group | Patient ID | Age (yr) | Gender | Estimated seroconversion date (yr) | Yr sampled (t0) | Period (yrs) between t0 and t3 samples | CD4 decay (cells/μl/yr) | CD4 count (cells/μl) at t3 | Mean VL (log copies HIV-RNA/ml) | HIV subtype | HLA allele(s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VNP | VNP-1 | 33 | Male | 2007 | 2008 | 3.3 | −74 | 632 | 5.0 | B | A*0301, A*3201, B*4403, B*4901, Cw*0701, Cw*1601 |
| VNP-2 | 30 | Male | 2008 | 2009 | 3.1 | −56 | 999 | 4.3 | B | A*0201, A*3201, B*4402, B*4402, Cw*0501, Cw*0501 | |
| VNP-3 | 28 | Male | 2006 | 2008 | 2.7 | 16 | 593 | 4.7 | B | A*0201, A*0201, B*0702, B*5101, Cw*0702, CW*1502 | |
| VNP-4 | 31 | Male | 2006 | 2008 | 2.6 | 10 | 783 | 4.6 | CRF19 | A*2902, A*6802, B*4403, B*5301, Cw*0401, Cw*1601 | |
| SP | SP-1 | 40 | Male | 2000 | 2001 | 3.1 | −115 | 468 | 4.4 | B | A*0201, A*6802, B*1402, B*1801, Cw*0501, Cw*0802 |
| SP-2 | 47 | Male | 2007 | 2008 | 3.2 | −117 | 342 | 4.2 | B | A*1101, A*3001, B*1302, B*1501, Cw*0303, Cw*0602 | |
| SP-3 | 43 | Male | 2005 | 2007 | 2.6 | −121 | 34 | 4.1 | B | A*2402, A*2601, B*4405, B*5101, Cw*0202, Cw*1402 | |
| SP-4 | 38 | Male | 2006 | 2007 | 2.1 | −234 | 352 | 5.0 | B | A*0301, A*3002, B*1801, B*3503, Cw*04, Cw*05 | |
| SP-5 | 44 | Male | 2007 | 2008 | 2.3 | −110 | 216 | 4.5 | B | A*0301, A*2902, B*4001, B*4403, Cw*0304, Cw*1601 |
a
For the epidemiological data, the age, estimated seroconversion date, time between samples, CD4 counts at time point t3, CD4 decays, mean viral load, HIV-1 subtype, and HLAs are detailed for each individual. The VNP and SP groups showed differences in CD4 counts and CD4 decays but not in mean viral loads.